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Pfizer Bioprocessing R&D is focused on developing enabling technologies that will reduce capital and 
operational expenses, decrease equipment scale, increase automation and utilize fewer FTEs.  
To realize this vision, Purification Process Development has piloted new technologies and operational strategies 
that have enabled a fully integrated downstream process.  Our current work has demonstrated a continuous 
process that includes tangential flow filtration harvest from a perfusion bioreactor, Protein A capture, inline viral 
inactivation/conditioning and AEX polishing.  This process was fully automated and demonstrated at the 100 L 
scale.   We have also shown feasibility of multi-day virus reduction filter operation and a continuous 
ultrafiltration/diafiltration using counter-current single-pass tangential flow filtration.  These technologies and 
strategies are critical elements of our long term goal of establishing a fully integrated process from bioreactor to 
drug substance.  With this process, we hope to remove product supply as a critical path activity for both 
toxicology and clinical needs. 
 
